同种异体干细胞移植治疗原发性皮肤t细胞淋巴瘤的新型低强度调节方案。

Clinical Hematology International Pub Date : 2021-06-12 eCollection Date: 2021-06-01 DOI:10.2991/chi.k.210529.001
Maria Stamouli, Konstantinos Gkirkas, Aggeliki Karagiannidi, Theodoros Iliakis, Spiros Chondropoulos, Thomas Thomopoulos, Vassiliki Nikolaou, Vassiliki Pappa, Evangelia Papadavid, Panagiotis Tsirigotis
{"title":"同种异体干细胞移植治疗原发性皮肤t细胞淋巴瘤的新型低强度调节方案。","authors":"Maria Stamouli,&nbsp;Konstantinos Gkirkas,&nbsp;Aggeliki Karagiannidi,&nbsp;Theodoros Iliakis,&nbsp;Spiros Chondropoulos,&nbsp;Thomas Thomopoulos,&nbsp;Vassiliki Nikolaou,&nbsp;Vassiliki Pappa,&nbsp;Evangelia Papadavid,&nbsp;Panagiotis Tsirigotis","doi":"10.2991/chi.k.210529.001","DOIUrl":null,"url":null,"abstract":"<p><p>The prognosis of patients with mycosis fungoides (MF) and Sezary Syndrome (SS) varies greatly, from near normal life expectancy in patients with early stage, to a median survival of less than 2 years for those diagnosed with advanced stage disease. Initial response to treatment is almost always followed by relapse and, finally, most of patients enter a phase of advanced multi-drug resistant disease with a short life expectancy after multiple lines of treatment. Allogeneic stem cell transplantation (allo-SCT) is usually limited to patients with advanced disease resistant to multiple treatments. Retrospective registry-based studies have shown increased Non-relapse Mortality (NRM) rates in patients with poor performance status, as well as in patients treated with myeloablative conditioning regimens. Another major limitation of allo-SCT is the increased relapse rate which occurs in nearly 50% of the cases, and is probably due to the fact that only heavily pretreated patients with advanced disease are referred for allo-SCT. Due to the paucity of data, the ideal conditioning regimen which will provide the maximum therapeutic benefit without the cost of increased NRM is not currently known. In this article we present our experience with a novel regimen in the treatment of patients with advanced MF/SS.</p>","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/3b/CHI-3-2-72.PMC8432398.pdf","citationCount":"2","resultStr":"{\"title\":\"Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas.\",\"authors\":\"Maria Stamouli,&nbsp;Konstantinos Gkirkas,&nbsp;Aggeliki Karagiannidi,&nbsp;Theodoros Iliakis,&nbsp;Spiros Chondropoulos,&nbsp;Thomas Thomopoulos,&nbsp;Vassiliki Nikolaou,&nbsp;Vassiliki Pappa,&nbsp;Evangelia Papadavid,&nbsp;Panagiotis Tsirigotis\",\"doi\":\"10.2991/chi.k.210529.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The prognosis of patients with mycosis fungoides (MF) and Sezary Syndrome (SS) varies greatly, from near normal life expectancy in patients with early stage, to a median survival of less than 2 years for those diagnosed with advanced stage disease. Initial response to treatment is almost always followed by relapse and, finally, most of patients enter a phase of advanced multi-drug resistant disease with a short life expectancy after multiple lines of treatment. Allogeneic stem cell transplantation (allo-SCT) is usually limited to patients with advanced disease resistant to multiple treatments. Retrospective registry-based studies have shown increased Non-relapse Mortality (NRM) rates in patients with poor performance status, as well as in patients treated with myeloablative conditioning regimens. Another major limitation of allo-SCT is the increased relapse rate which occurs in nearly 50% of the cases, and is probably due to the fact that only heavily pretreated patients with advanced disease are referred for allo-SCT. Due to the paucity of data, the ideal conditioning regimen which will provide the maximum therapeutic benefit without the cost of increased NRM is not currently known. In this article we present our experience with a novel regimen in the treatment of patients with advanced MF/SS.</p>\",\"PeriodicalId\":10368,\"journal\":{\"name\":\"Clinical Hematology International\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/3b/CHI-3-2-72.PMC8432398.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Hematology International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2991/chi.k.210529.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Hematology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2991/chi.k.210529.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

蕈样真菌病(MF)和Sezary综合征(SS)患者的预后差异很大,早期患者的预期寿命接近正常,晚期患者的中位生存期不到2年。最初对治疗有反应后几乎总是复发,最后,大多数患者在接受多种治疗后进入晚期多重耐药疾病阶段,预期寿命较短。同种异体干细胞移植(allo-SCT)通常局限于对多种治疗产生耐药性的晚期疾病患者。基于登记的回顾性研究显示,在表现不佳的患者以及接受清骨髓调节方案治疗的患者中,非复发死亡率(NRM)增加。同种异体细胞移植的另一个主要限制是复发率的增加,复发率在近50%的病例中发生,这可能是由于只有经过大量预处理的晚期疾病患者才会进行同种异体细胞移植。由于缺乏数据,理想的调理方案将提供最大的治疗效益而不增加NRM的成本,目前尚不清楚。在这篇文章中,我们介绍了一种治疗晚期MF/SS患者的新方案的经验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas.

Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas.

Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas.

The prognosis of patients with mycosis fungoides (MF) and Sezary Syndrome (SS) varies greatly, from near normal life expectancy in patients with early stage, to a median survival of less than 2 years for those diagnosed with advanced stage disease. Initial response to treatment is almost always followed by relapse and, finally, most of patients enter a phase of advanced multi-drug resistant disease with a short life expectancy after multiple lines of treatment. Allogeneic stem cell transplantation (allo-SCT) is usually limited to patients with advanced disease resistant to multiple treatments. Retrospective registry-based studies have shown increased Non-relapse Mortality (NRM) rates in patients with poor performance status, as well as in patients treated with myeloablative conditioning regimens. Another major limitation of allo-SCT is the increased relapse rate which occurs in nearly 50% of the cases, and is probably due to the fact that only heavily pretreated patients with advanced disease are referred for allo-SCT. Due to the paucity of data, the ideal conditioning regimen which will provide the maximum therapeutic benefit without the cost of increased NRM is not currently known. In this article we present our experience with a novel regimen in the treatment of patients with advanced MF/SS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信